{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T23:11:36Z","timestamp":1768777896372,"version":"3.49.0"},"reference-count":27,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2021,6,5]],"date-time":"2021-06-05T00:00:00Z","timestamp":1622851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001260","name":"National Organization for Rare Disorders","doi-asserted-by":"publisher","award":["2015"],"award-info":[{"award-number":["2015"]}],"id":[{"id":"10.13039\/100001260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Pseudomyxoma peritonei (PMP) is a rare, slow-growing cancer characterized by progressive accumulation of intraperitoneal mucinous tumor deposits. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) cures approximately 50% of patients, but in unresectable and recurrent cases, treatment options are limited. Anti-angiogenic treatment is being explored as a potential therapeutic option. Using PMP patient samples, microvessel densities (immunostaining for CD31 and CD105) and pro-angiogenic factors were analyzed, and the proliferative response upon incubation with human umbilical cord vascular endothelial cells (HUVEC) was determined. Growth inhibition by anti-angiogenic drugs was analyzed in patient-derived xenograft models of PMP. PMP tumor tissues were found to be highly vascularized and contained key pro-angiogenic factors, in particular related to vascular endothelial growth factor (VEGF) signaling, but interestingly, high levels of fibroblast growth factor 2 were also detected. HUVEC proliferation was stimulated upon incubation with fresh tumor samples and the observed proliferation could be inhibited by VEGF pathway inhibitor bevacizumab. In xenograft models the two VEGF pathway inhibitors, bevacizumab and aflibercept, inhibited tumor growth. This work reemphasizes the importance of angiogenesis as a major driver in PMP and strengthens the preclinical rationale for continued exploration of angiogenesis inhibition in the hope of providing novel treatment to a group of patients that have few other treatment options.<\/jats:p>","DOI":"10.3390\/cancers13112819","type":"journal-article","created":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T23:59:55Z","timestamp":1623023995000},"page":"2819","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Anti-Angiogenic Treatment in Pseudomyxoma Peritonei\u2014Still a Strong Preclinical Rationale"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3528-7171","authenticated-orcid":false,"given":"Yvonne","family":"Andersson","sequence":"first","affiliation":[{"name":"Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953 Nydalen, 0424 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0697-9750","authenticated-orcid":false,"given":"Karianne G.","family":"Fleten","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953 Nydalen, 0424 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torveig W.","family":"Abrahamsen","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953 Nydalen, 0424 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenche","family":"Reed","sequence":"additional","affiliation":[{"name":"Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953 Nydalen, 0424 Oslo, Norway"},{"name":"Department of Research, Innovation and Education, Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953 Nydalen, 0424 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-8427","authenticated-orcid":false,"given":"Ben","family":"Davidson","sequence":"additional","affiliation":[{"name":"Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953 Nydalen, 0424 Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, 0310 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7409-0780","authenticated-orcid":false,"given":"Kjersti","family":"Flatmark","sequence":"additional","affiliation":[{"name":"Department of Tumor Biology, Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953 Nydalen, 0424 Oslo, Norway"},{"name":"Institute of Clinical Medicine, University of Oslo, 0310 Oslo, Norway"},{"name":"Department of Gastroenterological Surgery, Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953 Nydalen, 0424 Oslo, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,6,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1245\/s10434-020-08655-8","article-title":"Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method","volume":"28","author":"Carr","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.ejso.2012.06.552","article-title":"Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in pseudomyxoma peritonei","volume":"38","author":"Flatmark","year":"2012","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.ajpath.2014.03.004","article-title":"Orthotopic Animal Model of Pseudomyxoma Peritonei","volume":"184","author":"Dohan","year":"2014","journal-title":"Am. J. Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.4161\/cbt.8.15.8943","article-title":"Successful antiangiogenic combination therapy for pseudomyxoma peritonei with bevacizumab and capecitabine","volume":"8","author":"Sun","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12967-016-0877-x","article-title":"GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: A clinical and translational study","volume":"14","author":"Pietrantonio","year":"2016","journal-title":"J. Transl. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1245\/s10434-014-4335-9","article-title":"Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms","volume":"22","author":"Choe","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1245\/s10434-017-6147-1","article-title":"Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms","volume":"24","author":"Akin","year":"2017","journal-title":"Ann. Surg. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Flatmark, K., Reed, W., Halvorsen, T., S\u00f8rensen, O., Wiig, J.N., Larsen, S.G., Fodstad, \u00d8., and Giercksky, K.-E. (2007). Pseudomyxoma peritonei\u2014Two novel orthotopic mouse models portray the PMCA-I histopathologic subtype. BMC Cancer, 7.","DOI":"10.1186\/1471-2407-7-116"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4103\/eus.eus_7_17","article-title":"Assessing tumor angiogenesis in colorectal cancer by quantitative contrast-enhanced endoscopic ultrasound and molecular and immunohistochemical analysis","volume":"7","author":"Gheonea","year":"2018","journal-title":"Endosc. Ultrasound"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1096\/fj.02-0634rev","article-title":"CD105 is important for angiogenesis: Evidence and potential applications","volume":"17","author":"Duff","year":"2003","journal-title":"FASEB J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12029-017-0014-y","article-title":"Role of VEGF, CD105, and CD31 in the Prognosis of Colorectal Cancer Cases","volume":"50","author":"Mohamed","year":"2017","journal-title":"J. Gastrointest. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.rmed.2019.08.003","article-title":"VEGF and FGF-2: Promising targets for the treatment of respiratory disorders","volume":"156","author":"Laddha","year":"2019","journal-title":"Respir. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"549412","DOI":"10.1155\/2015\/549412","article-title":"Hypoxia-Inducible Factor-1 in Physiological and Pathophysiological Angiogenesis: Applications and Therapies","volume":"2015","author":"Zimna","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1007\/s13277-015-4198-0","article-title":"The clinical significance of vascular endothelial growth factor in malignant ascites","volume":"37","author":"Zhan","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.2147\/OTT.S51916","article-title":"VEGF is a target molecule for peritoneal metastasis and malignant ascites in gastric cancer: Prognostic significance of VEGF in ascites and efficacy of anti-VEGF monoclonal antibody","volume":"6","author":"Fushida","year":"2013","journal-title":"OncoTargets Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/humrep\/deg491","article-title":"Women with endometriosis have increased levels of placental growth factor in the peritoneal fluid compared with women with cystadenomas","volume":"18","author":"Suzumori","year":"2003","journal-title":"Hum. Reprod."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"44735","DOI":"10.18632\/oncotarget.8203","article-title":"Molecular and clinical significance of fibroblast growth factor 2 (FGF2\/bFGF) in malignancies of solid and hematological cancers for personalized therapies","volume":"7","author":"Akl","year":"2016","journal-title":"Oncotarget"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1634\/theoncologist.2014-0465","article-title":"Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor","volume":"20","author":"Zhao","year":"2015","journal-title":"Oncologist"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"100793","DOI":"10.1016\/j.tranon.2020.100793","article-title":"Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models","volume":"13","author":"Fleten","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1158\/1535-7163.MCT-13-0753","article-title":"Differential Antitumor Activity of Aflibercept and Bevacizumab in Patient-Derived Xenograft Models of Colorectal Cancer","volume":"13","author":"Chiron","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Albonici, L., Giganti, M.G., Modesti, A., Manzari, V., and Bei, R. (2019). Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20122970"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","article-title":"A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia","volume":"40","author":"Carr","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.humpath.2009.12.013","article-title":"Exploring the peritoneal surface malignancy phenotype\u2014a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models","volume":"41","author":"Flatmark","year":"2010","journal-title":"Hum. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/978-3-642-57054-4_4","article-title":"Histological grading with clinical relevance in gastric mucosa-associated lymphoid tissue (MALT) lymphoma","volume":"156","author":"Boot","year":"2000","journal-title":"Recent Results Cancer Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"61800","DOI":"10.18632\/oncotarget.18694","article-title":"MOC31PE immunotoxin-targeting peritoneal metastasis from epithelial ovarian cancer","volume":"8","author":"Andersson","year":"2017","journal-title":"Oncotarget"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/ijc.28158","article-title":"Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies","volume":"133","author":"Flatmark","year":"2013","journal-title":"Int. J. Cancer"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/11\/2819\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:11:11Z","timestamp":1760163071000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/11\/2819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,5]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,6]]}},"alternative-id":["cancers13112819"],"URL":"https:\/\/doi.org\/10.3390\/cancers13112819","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,5]]}}}